Vibeke Strand, MD / April W. Armstrong, MD, MPH - A New Take on TYK2 Inhibitors: Bridging Gaps in Psoriatic Arthritis Management With Novel Targeted Therapies

episode

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

4AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Week: Trump vs the Press, Meta’s AI Win, and the Turning Political Tide 22 min · 25 Sep 2026 · The Prof G Pod with Scott Galloway

Gabrielle Lyon Part 2 1h 1m · 25 Sep 2026 · unPAUSED with Dr. Mary Claire Haver

Report any issue

Source

Recorded04 Sep 2024

Publisherc.answersincme.com ↗

Handlerec:13096828

Show notes

Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in